Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
Harvard Business School
Moodys
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CHILDREN'S ADVIL

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Children's Advil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000102 Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets Completed National Center for Research Resources (NCRR) Phase 1/Phase 2 1969-12-31 This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).
NCT00000115 Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed National Eye Institute (NEI) Phase 2 1990-12-01 To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00000170 Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed National Eye Institute (NEI) Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
NCT00000170 Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed Jaeb Center for Health Research Phase 3 1999-04-01 - To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy - To develop more precise estimates of the success rates of amblyopia treatment - To identify factors that may be associated with successful treatment of amblyopia - To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available Extended Follow up of Study Patients - Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years. - Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Children's Advil

Condition Name

Condition Name for Children's Advil
Intervention Trials
Asthma 239
HIV Infections 177
Malaria 154
Leukemia 146
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Children's Advil
Intervention Trials
Leukemia 361
Disease 351
Attention Deficit Disorder with Hyperactivity 301
Syndrome 289
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Children's Advil

Trials by Country

Trials by Country for Children's Advil
Location Trials
France 534
Germany 512
United Kingdom 501
Australia 476
Italy 426
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Children's Advil
Location Trials
New York 922
Ohio 865
Pennsylvania 834
Florida 704
Massachusetts 674
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Children's Advil

Clinical Trial Phase

Clinical Trial Phase for Children's Advil
Clinical Trial Phase Trials
Phase 4 1366
Phase 3 1649
Phase 2/Phase 3 273
[disabled in preview] 1615
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Children's Advil
Clinical Trial Phase Trials
Completed 3514
Recruiting 1452
Not yet recruiting 829
[disabled in preview] 482
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Children's Advil

Sponsor Name

Sponsor Name for Children's Advil
Sponsor Trials
National Cancer Institute (NCI) 420
National Institute of Allergy and Infectious Diseases (NIAID) 203
M.D. Anderson Cancer Center 194
[disabled in preview] 150
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Children's Advil
Sponsor Trials
Other 8476
Industry 2609
NIH 1254
[disabled in preview] 110
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Medtronic
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.